REPONEX PHARMACEUTICALS A/S
CVR number: 30082346
Slotsmarken 18, 2970 Hørsholm
www.reponex.dk
Income statement (kDKK)
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Fiscal period length | 12 | 12 | 12 | 12 | 12 |
| Net sales | |||||
| Gross profit | |||||
| Costs of management | -5 780.00 | -7 517.00 | |||
| Employee benefit expenses | - 119.44 | ||||
| Other operating expenses | -1 827.86 | -2 144.99 | -12 603.84 | -5 497.00 | -9 083.00 |
| Total depreciation | - 390.35 | - 157.04 | |||
| EBIT | -2 337.66 | -2 302.03 | -12 603.84 | -11 277.00 | -16 600.00 |
| Other financial income | 0.16 | 0.03 | 66.00 | ||
| Other financial expenses | -21.49 | -80.78 | - 250.77 | -22.00 | -45.00 |
| Pre-tax profit | -2 358.99 | -2 382.81 | -12 854.58 | -11 299.00 | -16 579.00 |
| Income taxes | 505.07 | 877.91 | 2 971.42 | 1 855.00 | 2 233.00 |
| Net earnings | -1 853.92 | -1 504.90 | -9 883.16 | -9 444.00 | -14 346.00 |
Assets (kDKK)
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Intangible rights | 12 267.91 | 16 960.39 | 13 355.59 | 13 860.00 | 13 598.00 |
| Intangible assets total | 12 267.91 | 16 960.39 | 13 355.59 | 13 860.00 | 13 598.00 |
| Other tangible assets | 10.73 | 5.36 | 320.54 | 582.00 | 55.00 |
| Tangible assets total | 10.73 | 5.36 | 320.54 | 582.00 | 55.00 |
| Other non-current investments | 452.00 | ||||
| Investments total | 452.00 | ||||
| Long term receivables total | |||||
| Inventories total | 883.34 | 1 040.01 | 1 160.86 | ||
| Current owed by particip. interest comp. | 1 416.00 | ||||
| Prepayments and accrued income | 203.54 | 216.03 | 22.56 | 1 587.00 | 423.00 |
| Current other receivables | 633.79 | 865.37 | 961.90 | 802.00 | 1 547.00 |
| Current deferred tax assets | 964.51 | 1 185.95 | 1 483.48 | 1 855.00 | 2 233.00 |
| Short term receivables total | 1 801.84 | 2 267.35 | 2 467.94 | 4 244.00 | 5 619.00 |
| Cash and bank deposits | 2 537.91 | 135.75 | 11 403.25 | 2 830.00 | 1 938.00 |
| Cash and cash equivalents | 2 537.91 | 135.75 | 11 403.25 | 2 830.00 | 1 938.00 |
| Balance sheet total (assets) | 17 501.73 | 20 408.87 | 28 708.18 | 21 516.00 | 21 662.00 |
Equity and liabilities (kDKK)
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Share capital | 602.27 | 602.27 | 829.54 | 830.00 | 850.00 |
| Share premium account | 20 861.39 | 20 861.39 | |||
| Other reserves | 8 610.41 | 12 423.97 | 9 958.68 | 18 081.00 | 15 907.00 |
| Retained earnings | -13 286.80 | -18 954.29 | 26 466.17 | 9 444.00 | 14 346.00 |
| Profit of the financial year | -1 853.92 | -1 504.90 | -9 883.16 | -9 444.00 | -14 346.00 |
| Shareholders equity total | 14 933.34 | 13 428.44 | 27 371.23 | 18 911.00 | 16 757.00 |
| Non-current leasing loans | 162.64 | 295.00 | 234.00 | ||
| Provisions | 1 179.90 | 1 487.94 | |||
| Non-current other liabilities | -1 179.90 | -2 975.88 | |||
| Non-current deferred tax liabilities | 1 179.90 | 1 487.94 | |||
| Non-current liabilities total | 1 179.90 | 162.64 | 295.00 | 234.00 | |
| Current leasing loans | 286.00 | 217.00 | |||
| Current trade creditors | 1 193.93 | 1 858.21 | 745.68 | 1 606.00 | 2 659.00 |
| Other non-interest bearing current liabilities | 194.56 | 3 634.28 | 428.62 | 418.00 | 1 795.00 |
| Current liabilities total | 1 388.49 | 5 492.49 | 1 174.30 | 2 310.00 | 4 671.00 |
| Balance sheet total (liabilities) | 17 501.73 | 18 920.93 | 28 708.17 | 21 516.00 | 21 662.00 |
Try the full version of our system for free
Create your own estimates for any company
Valuation analysis
See instructions
... and more!
No registration needed.